

Innovid Reports First Quarter 2022 Financial Results

- Successfully completed the acquisition of TVSquared to establish an independent solution for global cross-platform TV measurement
- Delivered 30% year-over-year revenue growth to \$23.4 million excluding TVSquared and 44% year-over-year revenue growth to \$25.9 million on an as-reported basis
- Grew CTV revenue, excluding TVSquared, by 40% year-over-year
- CTV accounted for 47% of all revenue, excluding TVSquared, up from 44% in the prior year period

NEW YORK, May 6, 2022 /PRNewswire/ -- Innovid Corp. (NYSE: CTV) (the "Company"), an independent advertising platform for delivery, personalization and measurement of converged TV across linear, connected TV (CTV) and digital, today announced financial results for the first quarter ended March 31, 2022. First quarter 2022 financial results of the Company represent the combined performance of Innovid Corp. and one month of TVSquared (the "combined business"), which was acquired on February 28, 2022.

"Innovid delivered outstanding performance in the first quarter - achieving revenue growth of 30% year-over-year, excluding TVSquared, and exceeding our prior guidance. We successfully completed the strategic acquisition of TVSquared, expanding our measurement infrastructure to address the growing needs of marketers in today's converged TV marketplace," said Zvika Netter, Co-founder and CEO of Innovid. "Our integration efforts are progressing well, and we believe we are well-positioned to serve the fast-growing global CTV market through a unified, independent measurement platform, anchored to the backbone of our global ad server business. We remain optimistic about our growth prospects and opportunities for 2022 and beyond."

First Quarter Financial Highlights:

(All comparisons are to the first quarter of 2021)

- Revenue was \$25.9 million for the combined business, reflecting an increase of 44%.
 - Revenue excluding TVSquared was \$23.4 million, an increase of 30%.
 - CTV accounted for 47% of revenue excluding TVSquared, up from 44% in Q1 2021, demonstrating 40% year-over-year growth.
- Gross margin in the first quarter was 75%.
- Net loss was \$(7.4) million or \$(0.06) per share in the first quarter.
- Adjusted EBITDA was \$(3.0) million in the first quarter, representing a (12)% adjusted EBITDA margin.

First Quarter Business Highlights Include:

• <u>High CTV Growth</u>: Grew CTV revenue by 40% year-over-year driven by increased volume from existing customers as well as by sales to new customers. CTV accounted

- for 47% of revenue generated excluding TVSquared, up from 44% in Q1 2021.
- New Business Momentum: Closed new global advertiser clients including leading US TV advertisers General Motors and KFC.
- <u>International Market Adoption</u>: Increased international revenue by 56% year-over-year through an expanded measurement footprint outside the U.S. following the TVSquared acquisition and increased ad serving and personalization adoption into new markets from global advertisers.
- <u>Advanced Cross-Platform Measurement</u>: Completed acquisition of converged TV measurement platform <u>TVSquared</u>, on February 28, 2022, for \$100 million in cash, 11.5 million in Innovid stock, and 950 thousand fully vested stock options.
- <u>Bolstered NBCUniversal Partnership</u>: Named a certified ad serving partner in <u>NBCUniversal</u>'s Certified Measurement Program in addition to being tapped to provide the infrastructure enabling behavior-based sequential storytelling on Peacock.

Second Quarter 2022 Outlook

Innovid is providing the following financial guidance for the second quarter of 2022:

- Revenue is expected to be in the range of \$33 million to \$35 million, reflecting 44% to 53% year-over-year growth on an as-reported basis, and 18% to 25% year-over-year growth on a pro forma basis when including TVSquared revenue.
- Adjusted EBITDA is expected to be in the range of negative \$(3.5) million to negative \$(1.5) million.
- TVSquared contribution to the quarterly revenue is expected to exceed \$6 million.

Full Year 2022 Outlook

Innovid is providing the following updated financial guidance for the full year of 2022, which includes the TVSquared acquisition:

- Revenue is expected to be in the range of \$135 million to \$140 million including TVSquared, a year-over-year increase of approximately 50% to 55% growth on an asreported basis, and 24% to 29% year-over-year growth on a pro forma basis when including TVSquared revenue.
- TVSquared's contribution to the revenue growth is expected to exceed \$25 million for the period from March 1 to December 31.
- Adjusted EBITDA, excluding TVSquared, is expected to remain positive in line with previous guidance.

Conference Call

Innovid will host a conference call and live webcast to discuss its first quarter 2022 financial results and business highlights today at 8:30 a.m. Eastern Time. Speakers will include Zvika Netter, Co-founder and Chief Executive Officer, Tanya Andreev-Kaspin, Chief Financial Officer and Tal Chalozin, Co-founder and Chief Technology Officer. To access the conference call, dial 877-407-0833 for the U.S. or Canada, or +1-201-389-0862 for international callers. The webcast will be available live on the Investors section of the Company's website at https://investors.innovid.com/. Additionally, an archived webcast of the conference call will be made available on the Innovid website following the call.

Non-GAAP Measures

Innovid prepares unaudited condensed consolidated financial statements in accordance with U.S. generally accepted accounting principles ("GAAP"). Innovid also discloses and discusses non-GAAP financial measures such as Adjusted EBITDA and Adjusted EBITDA margin. Innovid believes that these measures are relevant and provide useful information to investors by providing a baseline for evaluation and comparing its operating performance against that of other companies in Innovid's industry. Adjusted EBITDA is defined as net income (loss) attributable to Innovid, excluding (1) depreciation and amortization, (2) stock-based compensation, (3) finance expense, net, (4) transaction related expenses, (5) acquisition related expenses, (6) taxes on income and (7) other one-time items. We calculate Adjusted EBITDA Margin as Adjusted EBITDA divided by total revenue.

The non-GAAP financial measures that Innovid uses may not be comparable to similarly titled measures reported by other companies. Also, in the future, Innovid may disclose different non-GAAP financial measures in order to help its investors meaningfully evaluate and compare its results of operations to its previously reported results of operations or to those of other companies in Innovid's industry. Non-GAAP financial measures should be considered in addition to, and not as a substitute for, measures of financial performance prepared in accordance with GAAP.

Innovid uses Adjusted EBITDA and Adjusted EBITDA margin as measures of operational efficiency to understand and evaluate its core business operations. Innovid believes these non-GAAP financial measures are useful to investors for period to period comparisons of its core business and for understanding and evaluating trends in its operating results on a consistent basis by excluding items that are not viewed as indicative of its core operating performance.

Non-GAAP financial measures have limitations as analytical tools and should not be considered in isolation or as substitutes for an analysis of our results as reported under GAAP.

Innovid has provided a reconciliation of Adjusted EBITDA to net (loss) income and Adjusted EBITDA Margin to net (loss) income margin, the most directly comparable GAAP measures, for the historical period in the appendix hereto but is not able to provide a reconciliation of the projected non-GAAP measures for the second quarter of 2022 or the full-year 2022, without unreasonable effort, due to the unknown effect, timing and potential significance of: taxes on income in multiple jurisdictions, finance expenses including valuations, and purchase price allocation yet to be finalized. These items have in the past, and may in the future, significantly affect GAAP results in a particular period.

Forward-Looking Statements

This press release includes "forward-looking statements" within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1996. The Company's actual results may differ from its expectations, estimates and projections and consequently, you should not rely on these forward-looking statements as predictions of future events. Words such as "expect," "estimate," "project," "budget," "forecast," "anticipate," "intend," "plan," "may," "will," "could," "should," "believes," "predicts," "potential," "continue," "aim," and similar expressions are intended to identify such forward-looking statements. These

forward-looking statements include, without limitation, the Company's expectations regarding its future financial results, expected growth and the expected benefits resulting from its partnerships. These forward-looking statements involve significant risks and uncertainties that could cause the actual results to differ materially from the expected results, including Innovid's ability to raise financing in the future, success in retaining or recruiting officers, key employees or directors, changes in applicable laws or regulations, Innovid's ability to maintain and expand relationships with advertisers, decreases and/or changes in CTV audience viewership behavior. Innovid's ability to make the right investment decisions and to innovate and develop new solutions, the accuracy of Innovid's estimates of market opportunity, forecasts of market growth and projections of future financial performance, the extent of investment required in Innovid's sales and marketing efforts, Innovid's ability to effectively manage its growth, the impact of the Covid-19 pandemic, the risk of continued inflation and other macroeconomic events, acquisition related risks, and other important factors discussed under the caption "Risk Factors" in Innovid's Annual Report on Form 10-K filed with the SEC on March 18, 2022, as such factors may be updated from time to time in its other filings with the SEC, accessible on the SEC's website at www.sec.gov and the Investors Relations section of Innovid's website at investors, innovid, com. Most of these factors are outside the Company's control and are difficult to predict. The Company cautions not to place undue reliance upon any forwardlooking statements, including projections, which speak only as of the date made. The Company does not undertake or accept any obligation to release publicly any updates or revisions to any forward-looking statements to reflect any change in its expectations or any change in events, conditions or circumstances on which any such statement is based.

About Innovid

Innovid (NYSE:CTV) powers advertising delivery, personalization, measurement and outcomes across linear, CTV and digital for some of the world's largest brands. Through a global infrastructure that enables cross-platform ad serving, data-driven creative, and currency-grade measurement, Innovid offers its clients always-on intelligence to optimize advertising investment across channels, platforms, screens, and devices. Innovid is an independent platform that leads the market in converged TV innovation, through proprietary technology and exclusive partnerships designed to reimagine TV advertising. Headquartered in New York City, Innovid serves a global client base through offices across the Americas, Europe, and Asia Pacific. To learn more, visit innovid.com or follow us on LinkedIn or Twitter.

Investor Relations:

Brinlea Johnson ir@innovid.com

Media:

Chris Harihar chris@crenshawcomm.com

INNOVID, CORP. AND ITS SUBSIDIARIES CONDENSED CONSOLIDATED BALANCE SHEETS (In thousands, except stock and per stock data)

ASSETS Current ASSETS: Cash and cash equivalents \$ \$ \$ \$ \$ \$ \$ \$ \$		March 31, 2022 (Unaudited)	December 31, 2021
Cash and cash equivalents \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$	ASSETS	(Onaudited)	
Trade receivables, net (allowance for doubtful accounts of \$74 and \$81 at March 31, 2022 and 38,766 35,422 December 31 2021, respectively) 38,766 35,422 Prepaid expenses and other current assets 99,778 195,249 NON-CURRENT ASSETS: 303 310 Long-term deposit 303 310 Long-term restricted deposits 453 462 Property and equipment, net 6,599 4,840 Goodwill 97,202 4,555 Intangible assets, net 59,265 — Right of use lease asset 3,497 — Other non-current assets 542 116 Total anssets 167,861 10,283 TOTAL ASSETS 258,639 205,532 LIABILITIES AND STOCKHOLDERS' EQUITY 258,639 255,639 CURRENT LIABILITIES 3,791 5,026 Employees and payroll accruals 10,159 7,742 Accrude depenses and other current liabilities 6,000 6,000 Lease liabilities - non-current portion 3,253 — Total c	CURRENT ASSETS:		
Trade receivables, net (allowance for doubtful accounts of \$74 and \$81 at March 31, 2022 and becember 31 2021, respectively) 45,441 150,698 December 31 2021, respectively) 33,766 35,422 Prepaid expenses and other current assets 6,571 3,131 Total current assets 90,778 195,249 NON-CURRENT ASSETS: 90,778 195,249 Long-term deposit 303 310 Long-term deposit 453 462 Codowill 97,202 4,555 Intangible assets, net 6,599 4,840 Goodwill 97,202 4,555 Intangible assets, net 59,265 5-26 Right of use lease asset 3,497 -6 Other non-current assets 167,861 10,283 TOTAL ASSETS \$ \$ CURRENT LIABILITIES \$ \$ Trade payables 3,791 5,026 Employees and payroll accruals 3,791 5,026 Employees and payroll accruals 4,183 3,025 Current portion of long-term debt 6,000 </td <td>Cash and cash equivalents</td> <td></td> <td></td>	Cash and cash equivalents		
December 31 2021, respectively) 38,766 35,422 Prepaid expenses and other current assets 6,51 3,131 Total current assets 90,778 195,249 NON-CURRENT ASSETS:	•	45,441	156,696
Prepaid expenses and other current assets 90,776 195,249 Total current assets 90,776 195,249 NON-CURRENT ASSETS:		39 766	35 422
Total current assets 90,778 195,249 NON-CURRENT ASSETS: 303 310 Long-term deposit 453 462 Property and equipment, net 6,599 4,800 Goodwill 97,202 4,555 Intangible assets, net 3,497 - Right of use lease asset 3,497 - Other non-current assets 167,861 10,283 TOTAL ASSETS \$ \$ ILABILITIES AND STOCKHOLDERS' EQUITY \$ \$ CURRENT LIABILITIES: 10,159 7,742 Accused expenses and other current liabilities 3,791 5,026 Employees and payroll accruals 10,159 7,742 Accused expenses and other current liabilities 4,183 3,082 Current portion of long-term debt 6,000 6,000 Lease liabilities - current portion 3,253 - Non-Current liabilities 3,253 - Cother non-current liabilities 3,253 - Total current liabilities 3,253 -		•	
Long-term deposit 303 310 Long-term restricted deposits 453 462 Property and equipment, net 6,599 4,840 Goodwill 97,202 4,555 Intangible assets, net 59,265 4,565 Right of use lease asset 3,497 Other non-current assets 542 116 Total non-current assets 167,861 10,283 Total ASSETS \$ \$ LIABILITIES AND STOCKHOLDERS' EQUITY \$ \$ CURRENT LIABILITIES: 10,159 7,742 Accrued payables 3,791 5,026 Employees and payroll accruals 10,159 7,742 Accrued expenses and other current liabilities 2,185 2,185 Current portion of long-term debt 6,000 6,000 Lease liabilities - current portion 3,253 - NON-CURRENT LIABILITIES: 25,814 21,850 Lease liabilities - non-current liabilities 29,09 22,427 Total current liabilities 29,09 22,427 </td <td>' '</td> <td></td> <td></td>	' '		
Long-term restricted deposits	NON-CURRENT ASSETS:		· · · · · · · · · · · · · · · · · · ·
Property and equipment, net 6,599 4,840 Goodwill 97,202 4,555 Intangible assets, net 59,265 - Right of use lease asset 3,497 - Other non-current assets 542 116 Total non-current assets 167,861 10,283 TOTAL ASSETS 258,639 205,532 LIABILITIES AND STOCKHOLDERS' EQUITY 3,791 5,026 Employees and payroll accruals 10,159 7,742 Accrued expenses and other current liabilities 4,183 3,082 Current portion of long-term debt 6,000 6,000 Lease liabilities - current portion 1,681 - NON-CURRENT LIABILITIES: 25,814 21,850 NON-CURRENT LIABILITIES 10,471 3,455 Warrants liability 10,471 3,455 Warrants liability 29,909 22,427 Total non-current liabilities 29,909 22,427 Total LIABILITIES 55,723 44,277 Total LIABILITIES 55,723 44,277			
Square S	·		
Intangible assets, net S9,265 Right of use lease asset 3,497		,	
Right of use lease asset 3,497 — Other non-current assets 167,861 1168 TOTAL ASSETS \$ \$ LIABILITIES AND STOCKHOLDERS' EQUITY \$ 255,639 205,532 CURRENT LIABILITIES: Trade payables 3,791 5,026 Employees and payroll accruals 10,159 7,742 Accrued expenses and other current liabilities 4,183 3,082 Current portion of long-term debt 6,000 6,000 6,000 Lease liabilities - current portion 25,814 21,850 NON-CURRENT LIABILITIES: 25,814 21,850 Use as liabilities - non-current portion 3,253 — Other non-current liabilities 10,471 3,455 Warrants liability 16,185 18,972 TOTAL LIABILITIES 29,909 22,427 TOTAL LIABILITIES 29,909 22,427 TOTAL LIABILITIES 29,909 22,427 COMMITMENTS AND CONTINGENT LIABILITIES 5,723 44,277 STOCKHOLDERS' EQUITY (DEFICIT): 2		·	4,555
Other non-current assets 542 116 Total non-current assets 1 167,861 10,283 TOTAL ASSETS \$ \$ \$ \$ \$ \$ \$ 258,639 205,532 LIABILITIES AND STOCKHOLDERS' EQUITY CURRENT LIABILITIES: Trade payables 3,791 5,026 Employees and payroll accruals 10,159 7,742 Accrued expenses and other current liabilities 4,183 3,082 Current portion of long-term debt 6,000 6,000 Lease liabilities - current portion 1,681 Total current liabilities 25,814 21,850 NON-CURRENT LIABILITIES: 3,253 Lease liabilities - non-current portion 3,253 Other non-current liabilities 10,471 3,455 Warrants liability 16,185 18,972 Total LABILITIES COMMITMENTS AND CONTINGENT LIABILITIES 29,909 22,427 TOTAL LABILITIES 55,723 44,277 Common stocks of \$0,0001 par value - Authorized: 500,000,000 and 500,000,000 at March 31, 2022 and December 31, 2021, respectively 13 12		·	_
TOTAL ASSETS \$ 258,639 \$ 205,532 LIABILITIES AND STOCKHOLDERS' EQUITY CURRENT LIABILITIES: Trade payables 3,791 5,026 Employees and payroll accruals 10,159 7,742 Accrued expenses and other current liabilities 4,183 3,082 Current portion of long-term debt 6,000 6,000 Lease liabilities - current portion 1,681 - Total current liabilities 25,814 21,850 NON-CURRENT LIABILITIES: 3,253 - Clease liabilities - non-current portion 3,253 - Other non-current liabilities 10,471 3,455 Warrants liability 16,185 18,972 Total non-current liabilities 29,909 22,427 TOTAL LIABILITIES 29,909 22,427 COMMITMENTS AND CONTINGENT LIABILITIES 55,723 44,277 Common stocks of \$0,0001 par value - Authorized: 500,000,000 and 500,000,000 at March 31, 2022 and 202 a	· · ·	,	116
LIABILITIES AND STOCKHOLDERS' EQUITY CURRENT LIABILITIES Suppose the parables Suppo	Total non-current assets	167,861	10,283
CURRENT LIABILITIES AND STOCKHOLDERS' EQUITY CURRENT LIABILITIES: Trade payables 3,791 5,026 Employees and payroll accruals 10,159 7,742 13,082 10,159 1,081 1	TOTAL ASSETS	•	*
CURRENT LIABILITIES: 3,791 5,026 Trade payables 3,791 5,026 Employees and payroll accruals 10,159 7,742 Accrued expenses and other current liabilities 4,183 3,082 Current portion of long-term debt 6,000 6,000 Lease liabilities - current portion 1,681 — Total current liabilities 25,814 21,850 NON-CURRENT LIABILITIES: 25,814 21,850 Lease liabilities - non-current portion 3,253 — Other non-current liabilities 10,471 3,455 Warrants liability 16,185 18,972 Total non-current liabilities 29,909 22,427 TOTAL LIABILITIES 55,723 44,277 COMMITMENTS AND CONTINGENT LIABILITIES STOCKHOLDERS' EQUITY (DEFICIT): STOCKHOLDERS' EQUITY (DEFICIT): Common stocks of \$0.0001 par value - Authorized: 500,000,000 and 500,000,000 at March 31, 2022 and 13 12 Accumulated apid-in capital 342,828 293,719 Accumulated deficit (139,925) (132,476) Total sto		258,639	205,532
Trade payables 3,791 5,026 Employees and payroll accruals 10,159 7,742 Accrued expenses and other current liabilities 4,183 3,082 Current portion of long-term debt 6,000 6,000 Lease liabilities - current portion 1,681 — Total current liabilities 25,814 21,850 NON-CURRENT LIABILITIES: 25,814 21,850 Lease liabilities - non-current portion 3,253 — Other non-current liabilities 10,471 3,455 Warrants liability 16,185 18,972 Total non-current liabilities 29,909 22,427 TOTAL LIABILITIES 55,723 44,277 COMMITMENTS AND CONTINGENT LIABILITIES 55,723 44,277 COMMITMENTS AND CONTINGENT LIABILITIES 55,723 44,277 Common stocks of \$0.0001 par value - Authorized: 500,000,000 and 500,000,000 at March 31, 2022 and 13 12 March 31, 2022 and December 31, 2021, respectively; Issued and outstanding: 132,088,772 and 119,017,380 at March 31, 342,828 293,719 Additional paid-in capital			
Employees and payroll accruals 10,159 7,742 Accrued expenses and other current liabilities 4,183 3,082 Current portion of long-term debt 6,000 6,000 Lease liabilities - current portion 1,681 — Total current liabilities 25,814 21,850 NON-CURRENT LIABILITIES: 25,814 21,850 Other non-current portion 3,253 — Other non-current liabilities 10,471 3,455 Warrants liability 16,185 18,972 Total non-current liabilities 29,909 22,427 Total non-current liabilities 29,909 22,427 COMMITMENTS AND CONTINGENT LIABILITIES 55,723 44,277 COMMITMENTS AND CONTINGENT LIABILITIES STOCKHOLDERS' EQUITY (DEFICIT): Common stocks of \$0.0001 par value - Authorized: 500,000,000 and 500,000,000 at March 31, 3 1 2022 and December 31, 2021, respectively; Issued and outstanding: 132,088,772 and 119,017,380 at 4 4 3 1 March 31, 2022 and paid-in capital 342,828 293,719 2 2 4 2		0.704	F 000
Accrued expenses and other current liabilities 4,183 3,082 Current portion of long-term debt 6,000 6,000 Lease liabilities - current portion 1,681 — Total current liabilities 25,814 21,850 NON-CURRENT LIABILITIES: 3,253 — Other non-current liabilities 10,471 3,455 Warrants liability 16,185 18,972 Total non-current liabilities 29,909 22,427 Total non-current liabilities 29,909 22,427 COMMITMENTS AND CONTINGENT LIABILITIES 55,723 44,277 STOCKHOLDERS' EQUITY (DEFICIT): Common stocks of \$0,0001 par value - Authorized: 500,000,000 and 500,000,000 at March 31, 2022 and 55,723 44,277 March 31, 2022 and 13 12 Additional paid-in capital 342,828 293,719 Accumulated deficit (139,925) (132,476) Total stockholders' equity 161,255 161,255		,	-,
Current portion of long-term debt 6,000 6,000 Lease liabilities - current portion 1,681 — Total current liabilities 25,814 21,850 NON-CURRENT LIABILITIES: 25,814 21,850 Lease liabilities - non-current portion 3,253 — Other non-current liabilities 10,471 3,455 Warrants liability 16,185 18,972 Total non-current liabilities 29,909 22,427 TOTAL LIABILITIES 55,723 44,277 COMMITMENTS AND CONTINGENT LIABILITIES 55,723 44,277 Common stocks of \$0.0001 par value - Authorized: 500,000,000 and 500,000,000 at March 31, 2022 and 55,723 44,277 Common stocks of \$0.0001 par value - Authorized: 500,000,000 and 500,000,000 at March 31, 2022 and December 31, 2021, respectively; Issued and outstanding: 132,088,772 and 119,017,380 at March 31, 2022 and December 31, 2021, respectively 13 12 Additional paid-in capital 342,828 293,719 Accumulated deficit (139,925) (132,476) Total LIABILITIES AND STOCKHOLDERS' FOULTY \$		•	,
Lease liabilities - current portion 1,681 — Total current liabilities 25,814 21,850 NON-CURRENT LIABILITIES: — Lease liabilities - non-current portion 3,253 — Other non-current liabilities 10,471 3,455 Warrants liability 16,185 18,972 Total non-current liabilities 29,909 22,427 TOTAL LIABILITIES 55,723 44,277 COMMITMENTS AND CONTINGENT LIABILITIES STOCKHOLDERS' EQUITY (DEFICIT): STOCKHOLDERS' EQUITY (DEFICIT): Common stocks of \$0.0001 par value - Authorized: 500,000,000 and 500,000,000 at March 31, 2022 and December 31, 2021, respectively; Issued and outstanding: 132,088,772 and 119,017,380 at 342,828 March 31, 2022 and December 31, 2021, respectively 3 42,828 293,719 Additional paid-in capital 342,828 293,719 Accumulated deficit (139,925) (132,476) Total LIABILITIES AND STOCKHOLDERS' FOULTY \$ \$,	,
NON-CURRENT LIABILITIES: Lease liabilities - non-current portion 3,253 — Other non-current liabilities 10,471 3,455 Warrants liability 16,185 18,972 Total non-current liabilities 29,909 22,427 TOTAL LIABILITIES 55,723 44,277 COMMITMENTS AND CONTINGENT LIABILITIES 55,723 44,277 STOCKHOLDERS' EQUITY (DEFICIT): Common stocks of \$0.0001 par value - Authorized: 500,000,000 and 500,000,000 at March 31, 2022 and December 31, 2021, respectively; Issued and outstanding: 132,088,772 and 119,017,380 at 13 12 Additional paid-in capital 342,828 293,719 Accumulated deficit (139,925) (132,476) Total stockholders' equity \$ \$		1,681	· —
Lease liabilities - non-current portion 3,253 — Other non-current liabilities 10,471 3,455 Warrants liability 16,185 18,972 Total non-current liabilities 29,909 22,427 TOTAL LIABILITIES 55,723 44,277 COMMITMENTS AND CONTINGENT LIABILITIES 55,723 44,277 STOCKHOLDERS' EQUITY (DEFICIT): Common stocks of \$0.0001 par value - Authorized: 500,000,000 and 500,000,000 at March 31, 2022 and 2022 and December 31, 2021, respectively; Issued and outstanding: 132,088,772 and 119,017,380 at 13 12 Additional paid-in capital 342,828 293,719 Accumulated deficit (139,925) (132,476) Total LIABILITIES AND STOCKHOLDERS' FOULTY \$ \$		25,814	21,850
Other non-current liabilities 10,471 3,455 Warrants liability 16,185 18,972 Total non-current liabilities 29,909 22,427 TOTAL LIABILITIES 55,723 44,277 COMMITMENTS AND CONTINGENT LIABILITIES STOCKHOLDERS' EQUITY (DEFICIT): Common stocks of \$0.0001 par value - Authorized: 500,000,000 and 500,000,000 at March 31, 2022 and December 31, 2021, respectively; Issued and outstanding: 132,088,772 and 119,017,380 at Additional paid-in capital 342,828 293,719 Additional paid-in capital 342,828 293,719 Accumulated deficit (139,925) (132,476) Total stockholders' equity \$ \$		0.050	
Warrants liability 16,185 18,972 Total non-current liabilities 29,909 22,427 TOTAL LIABILITIES 55,723 44,277 COMMITMENTS AND CONTINGENT LIABILITIES STOCKHOLDERS' EQUITY (DEFICIT): STOCKHOLDERS' EQUITY STOCKHOLDERS' EQUITY STOCKHOLDERS' EQUITY STOCKHOLDERS' EQUITY STOCKHOLDERS' EQUITY STOCKHOLDERS' EQUITY 13 12 12 13 12	·		2.455
Total non-current liabilities 29,909 22,427 TOTAL LIABILITIES 55,723 44,277 COMMITMENTS AND CONTINGENT LIABILITIES STOCKHOLDERS' EQUITY (DEFICIT): Common stocks of \$0.0001 par value - Authorized: 500,000,000 and 500,000,000 at March 31, 2022 and Pecember 31, 2021, respectively; Issued and outstanding: 132,088,772 and 119,017,380 at Authorized: 500,000,000 and 500,000,000 at March 31, 2022 and 19,017,380 at Authorized: 500,000,000 and 500,000,000 at March 31, 2022 and 19,017,380 at Authorized: 500,000,000 and 500,000,000 at March 31, 2022 and 19,017,380 at Authorized: 500,000,000 and 500,000,000 at March 31, Authorized: 500,000,000,000 at March 31, Authorized: 500,000,000,000,000 at March 31, Authorized: 500,000,000,000,000,000,000 at March 31, Authorized: 500,000,000,000,000,000,000,000,000 at March 31, Authorized: 500,000,000,000,000,000,000,000,000,000			•
TOTAL LIABILITIES TOTAL LIABILITIES COMMITMENTS AND CONTINGENT LIABILITIES STOCKHOLDERS' EQUITY (DEFICIT): Common stocks of \$0.0001 par value - Authorized: 500,000,000 and 500,000,000 at March 31, 2022 and December 31, 2021, respectively; Issued and outstanding: 132,088,772 and 119,017,380 at March 31, 2022 and December 31, 2021, respectively Additional paid-in capital Accumulated deficit Total stockholders' equity \$ \$ \$ TOTAL LIABILITIES AND STOCKHOLDERS' FOULTY \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$,		
COMMITMENTS AND CONTINGENT LIABILITIES STOCKHOLDERS' EQUITY (DEFICIT): Common stocks of \$0.0001 par value - Authorized: 500,000,000 and 500,000,000 at March 31, 2022 and December 31, 2021, respectively; Issued and outstanding: 132,088,772 and 119,017,380 at March 31, 2022 and December 31, 2021, respectively Additional paid-in capital Accumulated deficit Total stockholders' equity TOTAL LIABILITIES AND STOCKHOLDERS' FOULTY			
STOCKHOLDERS' EQUITY (DEFICIT): Common stocks of \$0.0001 par value - Authorized: 500,000,000 and 500,000,000 at March 31, 2022 and December 31, 2021, respectively; Issued and outstanding: 132,088,772 and 119,017,380 at March 31, 2022 and December 31, 2021, respectively Additional paid-in capital Accumulated deficit Total stockholders' equity \$ 13 12 42,828 293,719 43,719 40,110,110,110,110,110,110,110,110,110,1		55,723	44,277
Common stocks of \$0.0001 par value - Authorized: 500,000,000 and 500,000,000 at March 31, 2022 and December 31, 2021, respectively; Issued and outstanding: 132,088,772 and 119,017,380 at March 31, 2022 and December 31, 2021, respectively Additional paid-in capital Accumulated deficit Total stockholders' equity \$ 13 12 42,828 293,719 Accumulated deficit (139,925) (132,476) Total stockholders' equity \$ \$ \$			
2022 and December 31, 2021, respectively; Issued and outstanding: 132,088,772 and 119,017,380 at March 31, 2022 and December 31, 2021, respectively Additional paid-in capital Accumulated deficit Total stockholders' equity \$ 13 12 42,828 293,719 413,725 (132,476) 7074 LIABULTIES AND STOCKHOLDERS' FOULTY \$ \$	·		
March 31, 2022 and December 31, 2021, respectively 13 12 Additional paid-in capital 342,828 293,719 Accumulated deficit (139,925) (132,476) Total stockholders' equity 202,916 161,255 TOTAL LIABILITIES AND STOCKHOLDERS' FOULTY \$ \$			
2022 and December 31, 2021, respectively 13 12 Additional paid-in capital 342,828 293,719 Accumulated deficit (139,925) (132,476) Total stockholders' equity 202,916 161,255 TOTAL LIABULTIES AND STOCKHOLDERS' FOULTY \$			
Additional paid-in capital 342,828 293,719 Accumulated deficit (139,925) (132,476) Total stockholders' equity 202,916 161,255 TOTAL LIABULTIES AND STOCKHOLDERS' FOULTY \$ \$			
Accumulated deficit (139,925) (132,476) Total stockholders' equity \$ 202,916 161,255 TOTAL LIABILITIES AND STOCKHOLDERS' FOULTY			
Total stockholders' equity TOTAL LIABILITIES AND STOCKHOLDERS' FOULTY \$ \$	· · · · · · · · · · · · · · · · · · ·	•	,
TOTAL LIABILITIES AND STOCKHOLDERS' FOLLITY			
TOTAL LIABILITIES AND STOCKHOLDERS EQUITY 258.639 205.532	• •		
	TOTAL LIADILITIES AND STUCKHULDERS EQUITY	258,639	205,532

INNOVID, CORP. AND ITS SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(In thousands, except stock and per stock data)

	Т	Three months ended March 31,			
		2022		2021	
		(Unaudited)		(Unaudited)	
Revenues	\$	25,862	\$	18,013	
Cost of revenues		6,344		3,862	
Gross profit		19,518		14,151	
Operating expenses:					
Research and development		7,329		5,297	
Sales and marketing		10,520		6,651	
General and administrative		11,466		2,391	
Total operating expenses		29,315		14,339	
Operating loss		(9,797)		(188)	
Finance expenses, net		(2,311)		1,569	
Loss before taxes		(7,486)		(1,757)	
Taxes on income		(37)		179	
Net loss		(7,449)		(1,936)	
Accretion of preferred stock to redemption value		_		(23,728)	
Net loss attributable to common stockholders	\$	(7,449)	\$	(25,664)	
Net loss per stock attributable to common stockholders					
Basic and diluted	\$	(0.06)	\$	(1.55)	
Weighted-average number of stocks used in computing net loss per stock attributable to common stockholders	·				
Basic and diluted		124,245,358		16,547,808	

INNOVID, CORP. AND ITS SUBSIDIARIES CONDENSED STATEMENTS OF CHANGES IN TEMPORARY EQUITY AND STOCKHOLDERS' EQUITY (DEFICIT)

(In thousands, except stock data)

	Temporar	y equity	Common	stocks	Treasury	/ stocks	Additional		Total	
	Number	Amount	Number	Amount	Number	Amount	paid-in capital	Accumulated deficit	stockholders' equity (deficit)	
Balance as of December 31, 2020 Accretion of preferred stock	73,690,340	\$ 86,997	16,275,609	\$ 2	1,914,328	\$ (1,629)	\$ 10	\$ (48,113)	\$ (49,730)	
to redemption value Stock-based	_	23,728	_	_	_	_	(586)	(23,142)	(23,728)	
compensation Stock options	_	_	_	_	_	_	280	_	280	
exercised Net loss	_	_	761,697 —	_	_	_	306	— (1,936)	306 (1,936)	
Balance as of March 31, 2021 (unaudited)	73,690,340	\$ 110,725	17,037,306	\$ 2	1,914,328	\$ (1,629)	\$ 10	\$ (73,191)	\$ (74,808)	
	Temporar	y equity	Common	on stocks Treasury stocks		Additional	Accumulated	Total		
	Number	Amount	Number	Amount	Number	Amount	paid-in capital	deficit	stockholders' equity	
Balance as of December 31, 2021 Common stocks and equity awards	_	_	119,017,380	\$ 12	_	_	\$ 293,719	\$ (132,476)	\$ 161,255	
issued for acquisition of TVS Stock-based	_	_	11,549,465	1	_	_	47,151	_	47,152	
compensation	_	_	_	_	_	_	1,496	_	1,496	
Stock options exercised Net loss Balance as of			1,521,927 —				462 —	(7,449)	462 (7,449)	
March 31, 2022 (unaudited)			132,088,772	\$ 13			\$ 342,828	\$ (139,925)	\$ 202,916	

INNOVID, CORP. AND ITS SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(In thousands, except stock and per stock data)

Three months ended March

	Three months ended March		
	31, 2022	2021	
Cash flows from operating activities:	(Unaudited)	(Unaudited)	
	\$	\$	
Net loss	(7,449)	(1,936)	
Adjustments to reconcile net loss to net cash used in operating activities:			
Depreciation and amortization	673	182	
Non-cash operating lease expense	431	_	
Stock-based compensation	1,496	280	
Change in fair value of warrants	(2,787)	1,349	
Non-cash interest expense	_	5	
Changes in operating assets and liabilities Decrease in trade receivables, net	163	5,800	
Increase in prepaid expenses and other operating assets	(1,950)	(365)	
Increase/ (decrease) in trade payables	(191)	265	
Increase/ (decrease) in employees and payroll accruals	1,704	(1,031)	
Decrease in operating lease liabilities	(410)	(1,001)	
Increase in accrued expenses and other operating liabilities	1,107	588	
Net cash (used in)/ provided by operating activities	(7,213)	5,137	
Cash flows from investing activities:			
Acquisition of business, net of cash acquired	(99,568)	_	
Internal use software capitalization	(1,671)	_	
Purchase of property and equipment	(97)	(164)	
Decrease in deposits	3	11	
Net cash used in investing activities	(101,333)	(153)	
Cash flows from financing activities:		(400)	
Repayment of acquisition liability	(2.190)	(126)	
Payment of SPAC merger transaction costs Proceeds from exercise of options	(3,180) 462	306	
Net cash (used in)/ provided by financing activities	(2,718)	180	
Increase/ (decrease) in cash, cash equivalents and restricted cash	(111,264)	5,164	
Cash, cash equivalents and restricted cash at the beginning of the year	157,158	16,092	
	\$	\$	
Cash, cash equivalents and restricted cash at the end of the period	45,894	21,256	
Supplemental disclosure of cash flows activities:			
(1) Cash paid during the period for:			
	\$	\$	
Income taxes paid, net of tax refunds	165	80	
	\$	\$	
Interest	61	60	
	<u>¢</u>	\$	
Acquiree stock options settled in cash attributed to post acquisition services	Ψ 96	Ψ	
(2) Non-cash transactions:			
	\$	\$	
Business combination consideration paid in stock	47,152	_	
Accretion of preferred stocks to redemption value	\$	\$	
Accretion of preferred stocks to redemption value		23,728	
Reconciliation of cash, cash equivalents, and restricted cash reported within the statement of			
financial position	45 444	00.005	
Cash and cash equivalents Long-term restricted deposits	45,441	20,825	
	\$ 453	<u>431</u>	
Total cash, cash equivalents, and restricted cash shown in the condensed consolidated statements of cash flows	45,894	21,256	
statements of Cash nows	70,007	21,200	

Key Metrics and Non-GAAP Financial Measures

Adjusted EBITDA

In addition to our results determined in accordance with US GAAP, we believe that certain non-GAAP financial measures, including Adjusted EBITDA and Adjusted EBITDA Margin, are useful in evaluating our business. We calculate Adjusted EBITDA Margin as Adjusted

EBITDA divided by total revenue. The following table presents a reconciliation of Adjusted EBITDA, a non-GAAP financial measure, to the most directly comparable financial measure prepared in accordance with GAAP.

	Three months ended March 31,						
•	2022	2021					
Net (loss)/income	\$ (7,449)	\$ (1,936)					
Net loss margin	(29) %	(11) %					
Depreciation and amortization	673	182					
Stock-based compensation	1,592	280					
Finance expense, net (a)	(2,311)	1,569					
Transaction related expenses (b)	228	_					
Acquisition related expenses (c)	4,203	_					
Other (d)	92	153					
Taxes on income	(37)	179					
Adjusted EBITDA	\$ (3,009)	\$ 427					
Adjusted EBITDA margin	(12) %	2 %					

- (a) Finance expense, net consists mostly of remeasurement expense related to our Argentinian subsidiary's monetary assets, liabilities and operating results, our interest expense and revaluation of our warrants.
- (b) Transaction related expenses consist of professional fees associated with the SPAC merger transaction and PIPE related SEC filings.
- (c) Acquisition related expenses consists of professional fees associated with the acquisition of TVSquared.
- (d) For the three months ended March 31, 2022, other consists of tax expense related to the exercise of stock options by a former employee. For the three months ended March 31, 2021, other consists predominantly of the loss related to a one-time loss from sale of fixed assets in our Israeli subsidiary.

C View original content: https://www.prnewswire.com/news-releases/innovid-reports-first-guarter-2022-financial-results-301541499.html

SOURCE INNOVID